Competitive testing the who 2010 vs the who 2017 grading of pancreas neuroendocrine neoplasia: data from a large international cohort study
Conclusions: the WHO-AJCC 2017 grading is at least equally per forming as the WHO-AJCC 2010 but allows the successful identification of the most aggressive PanNET subgroup. Grading is confirmed as probably the most powerful tool for patient survival prediction.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Endocrinology | International Medicine & Public Health | Neurology | Neurosurgery | Pancreas | Pancreatic Cancer | Statistics | Study | WHO